These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36520958)

  • 21. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
    Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
    Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
    Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
    Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
    Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
    Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    Moore KN; Pothuri B
    Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    Smith M; Pothuri B
    Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
    Xu Q; Li Z
    Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
    Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
    BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
    Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolving landscape of predictive biomarkers of response to PARP inhibitors.
    Thomas A; Murai J; Pommier Y
    J Clin Invest; 2018 May; 128(5):1727-1730. PubMed ID: 29664016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.
    Cancanelli L; Mengato D; Di Spazio L; Rivano M; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):32-35. PubMed ID: 34779394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
    Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
    Target Oncol; 2024 Jan; 19(1):1-11. PubMed ID: 37993604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
    Gamba T; Paparo J; Panepinto O; Dionisio R; Di Maio M; Vignani F
    Clin Genitourin Cancer; 2023 Oct; 21(5):509-516. PubMed ID: 37500375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
    Agarwal A; Baghmar S; Dodagoudar C; Qureshi S; Khurana A; Vaibhav V; Kumar G
    JCO Glob Oncol; 2021 Apr; 7():506-511. PubMed ID: 33852339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.